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Astrocytoma Cell Line
TO THE EDITOR: It has long been established clinically
that patients with neurofibromatosis Type 1 (NF1) have
an increased susceptibility to develop many central and
peripheral tumors. The nature of the genetic alterations
underlying NF1 have recently begun to be characterized.
It has been demonstrated that the NF1 gene plays a crit-
ical role as a tumor suppressor and that patients with
NF1 harbor mutations in the NF1 gene, which codes for
neurofibromin, a functional negative regulator of signal
transduction through Ras. Neurofibromatosis Type 1 is an
autosomal-dominant cancer predisposition syndrome in
which 15 to 20% of affected individuals develop astrocy-
tomas that are most commonly pilocytic.
The power of cell culture as a foundation of current mo-
lecular and cell biology is often not apparent to clinicians
in the direct daily management of their patients. In the ar-
ticle by Kurimoto, et al. (Kurimoto M, Hirashima Y, Ogii-
chi T, et al: Establishment and characterization of a nov-
el malignant astrocytoma cell line derived from a tumor
removed in a patient with neurofibromatosis Type 1. J
Neurosurg 94:301–308, February, 2001), the authors have
established in tissue culture an immortalized cell line
(TM-31) from a high-grade glioma in a patient with NF1.
Although malignant glioma lines are established routinely
in most laboratories in which intracranial tumors are stud-
ied, to date there has been no available established glioma
line from a patient with NF1. This cell line offers a unique
opportunity to study the genetic alterations, growth, and
invasive characteristics in vitro.
Pilocytic astrocytomas of the optic nerve are closely
associated with NF1, and allelic losses of the NF1 gene
region on chromosone 17q occur in sporadic pilocytic as-
trocytomas.6 Loss of neurofibromin expression has been
demonstrated to be an important primary genetic event in
the pathogenesis of NF1-associated astrocytomas.2,4 Be-
cause most of the pilocytic astrocytomas in these patients
are clinically benign in nature, it is likely that such a loss
is an early and primary event. Loss of neurofibromin ex-
pression is observed in the tumor and is associated with
elevated levels of Ras-guanosine triphosphate (GTP),4 re-
sults that support the role of neurofibromin as a critical
GTPase activating protein (Ras-GAP) in the molecular
pathogenesis of NF1 astrocytomas. The role of neurofi-
bromin in the genesis of sporadic astrocytomas is less
clear, with elevations of neurofibromin expression noted
by some authors; this indicates a role of neurofibromin in
attempting to reduce uncontrolled growth signals in these
cells, which is perhaps less a primary pathological event
in tumorigenesis but rather a secondary compensatory ele-
vation in these tumor cells.3,5 Last, a striking association
has been observed between the presence of optic glioma
and other central nervous system (CNS) tumors in NF1,
which is an association not seen between optic glioma and
non-CNS tumors in these patients, indicating that funda-
mental pathophysiological differences exist between pa-
tients with and without optic glioma.1
It is expected that the well-characterized line described
herein will provide molecular insights into genetic alter-
ations associated with gliomas in these patients, and per-
haps through differential display methods we may ulti-
mately learn how this tumor differs from gliomas that
occur in patients without neurofibromatosis. Molecular
profiling will ultimately shed light on potential mecha-
nisms of tumorigenesis and hopefully offer windows into
any therapeutic avenues in the treatment and/or preven-
tion of these tumors in the susceptible host. The availabil-
ity of the line to the American Type Culture Collection,
Riken Gene Bank, and the Japanese Cancer Resource
Bank should facilitate further characterization of the tu-
mor by other investigators to achieve these goals.
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RESPONSE: We appreciate Dr. Couldwell’s comments on
our article. The TM-31 cell line is a novel astrocytoma cell
line, which has been derived from a patient with NF1.
This cell line is unique in several ways. First, the cell line
shows decreased neurofibromin expression. Second, the
TM-31 cell line has a resistance to drug-induced morpho-
logical differentiation. Third, this line is susceptible to a
farnesyltransferase inhibitor (B1620). These observations
might be important clues for understanding tumorigenesis
in a patient with NF1, as well as the molecular biology
and pathogenesis of astrocytomas. Although characteriza-
tion of TM-31 cells has not been completed, the availabil-
ity of this cell line is important for further studies. We will
submit the TM-31 cell line to standard tissue culture
repositories such as the American Type Culture Collec-
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Correction
TO THE READERSHIP: The Journal of Neurosurgery
would like to apologize to Marmarou, et al. (Marmarou A,
Fatouros P, Barzó P, et al: Contribution of edema and ce-
rebral blood flow volume to traumatic brain swelling in
head-injured patients. J Neurosurg 93:183–193, August,
2000) for errors introduced during the printing of their
manuscript.









Combined measures of brain-tissue water, CBV, and CBF
in 31 severely head injured patients
Change
Water in Water Change CBF
Content Content Percent- CBV in CBV (ml/
(% H2O/ (% H2O/ age of (ml/100 (ml/100 min/100
Factor g tissue) g tissue) Swelling* g tissue) g tissue) g tissue)
mean 79.17 ✟1.82 ✟9.37† 4.50 ✆0.80 39.35
SD 1.60 1.60 8.73 1.32 1.32 10.31
* Percentage (change in volume/volume) ratio.
† p ✁ 0.0001 compared with the change in CBV.
